Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adalimumab
8%
Adult Patients
8%
Biologic Therapy
7%
Clinical Remission
20%
Clinical Response
8%
Clostridium Difficile Infection
11%
Colectomy
8%
Corticosteroids
12%
COVID-19
15%
Crohn's Disease
83%
Cuffitis
7%
Disease Activity
9%
During Pregnancy
12%
Endoscopic Phenotype
11%
Epi-IIRN
10%
Fecal Calprotectin
18%
Gastrointestinal Involvement
7%
Hazard Ratio
15%
Ileal Pouch-anal Anastomosis
20%
Ileocecal Resection
18%
Induction Therapy
8%
Inflammation
12%
Inflammatory Bowel Disease
100%
Infliximab
20%
Israel
12%
Israeli
11%
J-pouch
19%
Lung Transplantation
17%
Mediterranean Diet
9%
Mediterranean Diet Adherence
10%
Meta-analysis
10%
Microbial Composition
10%
Moderate to Severe
15%
Newly Diagnosed
17%
Non-associated
8%
Postoperative Recurrence
12%
Pouch
26%
Pouchitis
10%
Real-world Experience
10%
Retrospective Cohort Study
8%
Risk Factors
8%
Serological Response
8%
Severe Ulcerative Colitis
11%
Tertiary Care Centers
11%
Tofacitinib
18%
Tumor Necrosis Factor-α
32%
Ulcerative Colitis
40%
Upper Gastrointestinal Tract
10%
Ustekinumab
26%
Vedolizumab
22%
Medicine and Dentistry
Adalimumab
8%
Adverse Event
8%
Biological Product
10%
Biological Therapy
6%
Capsule Endoscopy
5%
Cohort Analysis
11%
Colectomy
22%
Colitis
19%
Colon
5%
Colonoscopy
5%
Crohn's Disease
46%
Disease Activity
16%
Diseases
40%
Dysplasia
11%
Faecal Calprotectin
24%
Fistula
9%
Hazard Ratio
15%
Ileo-Anal Pouch
19%
Ileocolonoscopy
6%
Ileostomy
6%
Infection
7%
Inflammation
20%
Inflammatory Bowel Disease
52%
Infliximab
23%
Limb
8%
Lung Transplantation
11%
Mediterranean Diet
10%
Neoplasm
7%
Patient Referral
10%
Patient with Crohn's Disease
25%
Patient with Inflammatory Bowel Disease
51%
Patient with Ulcerative Colitis
18%
Pediatrics
15%
Pouchitis
28%
Proctocolectomy
5%
Pulmonary Hypertension
6%
Quality of Life
7%
Real-World Data
11%
Recurrent Disease
24%
Retrospective Cohort Study
9%
Steroids
15%
Surgical Anastomosis
21%
Systematic Review
11%
TNF Inhibitor
7%
Tofacitinib
10%
Tumor Necrosis
7%
Tumor Necrosis Factor
34%
Ulcerative Colitis
42%
Ustekinumab
24%
Vedolizumab
22%